全部照片(2)
About This Item
經驗公式（希爾表示法）:
C17H21NO · HCl
CAS號碼:
分子量：:
291.82
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
推薦產品
形狀
solid
起源
Eli Lilly
儲存溫度
2-8°C
SMILES 字串
CNCC[C@@H](OC1=CC=CC=C1C)C2=CC=CC=C2.[H]Cl
InChI
1S/C17H21NO.ClH/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15;/h3-11,17-18H,12-13H2,1-2H3;1H/t17-;/m1./s1
InChI 密鑰
LUCXVPAZUDVVBT-UNTBIKODSA-N
基因資訊
human ... SLC6A2(6530)
尋找類似的產品？ 前往 產品比較指南
應用
(R)-Tomoxetine hydrochloride has been used as a noradrenaline reuptake inhibitor:
- to study the role of L-threo-3,4-dihydroxyphenylserine (L-DOPS) in the pathogenesis of Alzheimer′s disease in mice
- to study its effects on set shifting in rats
- to study its effects on rat brain as a result of its long-term use
生化／生理作用
(R)-Tomoxetine hydrochloride is an efficient inhibitor of presynaptic norepinephrine transporters. It also positively regulates the release of acetylcholine in the prefrontal cortex (PFC). (R)-Tomoxetine hydrochloride binds to the serotonin (5-HT) transporter. It is involved in blocking the cortical N-methyl-D-aspartate (NMDA) receptors.. (R)-Tomoxetine hydrochloride exhibits therapeutic effects against attention-deficit/hyperactivity disorder (ADHD) and comorbid oppositional defiant disorder (ODD).
去甲肾上腺素摄取阻滞剂。
特點和優勢
This compound is featured on the Biogenic Amine Transporters page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Eli Lilly. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
儲存類別代碼
11 - Combustible Solids
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
個人防護裝備
Eyeshields, Gloves, type N95 (US)
分析證明 (COA)
輸入產品批次/批號來搜索 分析證明 (COA)。在產品’s標籤上找到批次和批號，寫有 ‘Lot’或‘Batch’.。
Fatma Gür et al.
Biochemical and biophysical research communications, 534, 927-932 (2020-11-05)
Attention Deficit Hyperactivity Disorder (ADHD) is the most common psychiatric disorder reported particularly in children. Long-term use of antipsychotic drugs used in the treatment of ADHD has been shown to exert toxic effects on the brain. However, not enough research
Grazia Dell'Agnello et al.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 19(11), 822-834 (2009-09-01)
The primary aim of this study was to assess the efficacy of atomoxetine in improving ADHD and ODD symptoms in paediatric patients with ADHD and comorbid oppositional defiant disorder (ODD), non-responders to previous psychological intervention with parent support. This was
Rachel Kornfield et al.
Psychiatric services (Washington, D.C.), 64(4), 339-346 (2013-01-16)
This study assessed the effect of public health advisories issued between 2005 and 2007 by the U.S. Food and Drug Administration (FDA) on treatments of attention-deficit hyperactivity disorder (ADHD) and physician prescribing practices. Data obtained from the IMS Health National
Romano Arcieri et al.
Journal of child and adolescent psychopharmacology, 22(6), 423-431 (2013-01-31)
The purpose of this study was to assess the cardiovascular effects of drugs used for attention-deficit/hyperactivity disorder (ADHD) in children and adolescents treated in community care centers in Italy. This study was an open, prospective, observational study of youth with
Himanshu P Upadhyaya et al.
Psychopharmacology, 226(2), 189-200 (2013-02-12)
Treatment of attention-deficit/hyperactivity disorder (ADHD) has for many years relied on psychostimulants, particularly various formulations of amphetamines and methylphenidate. These are central nervous system stimulants and are scheduled because of their abuse potential. Atomoxetine (atomoxetine hydrochloride; Strattera®) was approved in
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務